Indications
Etragut Tablet is used for:
Moderately to severely active ulcerative colitis in adults.
Adult Dose
2 mg orally once daily, with or without food. If a dose is missed, take the next dose at the scheduled time. Do not double the dose.
Child Dose
2 mg orally once daily, with or without food. If a dose is missed, take the next dose at the scheduled time. Do not double the dose.
Renal Dose
2 mg orally once daily, with or without food. If a dose is missed, take the next dose at the scheduled time. Do not double the dose.
Administration
2 mg orally once daily, with or without food. If a dose is missed, take the next dose at the scheduled time. Do not double the dose.
Contra Indications
Recent (within 6 months) myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure, or Class III/IV heart failure. History or presence of Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker. Known hypersensitivity to the active substance or to any of the excipients. Patients with severe hepatic impairment.
Precautions
Infections: It can increase the risk of infections. Heart rhythm problems: May slow your heart rate, especially when first starting. Liver problems: Can raise liver enzymes. Report yellowing of eyes or skin, dark urine, or unexplained nausea. Blood tests may be needed. Eye problems: Can cause macular edema (swelling at the back of the eye), especially if you have diabetes or past eye disease. Report vision changes. Breathing problems: May cause shortness of breath or reduced lung function. High blood pressure: It may raise blood pressure. Monitoring is recommended. Skin cancers: Slightly increased risk of skin cancer. Use sun protection and report unusual skin changes. Vaccinations: Avoid live vaccines during treatment and for 4 weeks after stopping.
Pregnancy-Lactation
Not recommended for pregnant women, may cause fetal harm. Use effective contraception during and for 1 week after stopping therapy. Unknown if excreted in human milk; It should be used in breastfeeding women only if the potential benefit justifies the potential risk to the fetus.
Interactions
Avoid concomitant use with moderate/strong CYP2C9 and CYP3A4 inhibitors or inducers (e.g., fluconazole, rifampin), certain anti-arrhythmic drugs (e.g., metoprolol, atenolol, propranolol, Diltiazem, Verapamil), QT-prolonging drugs (e.g., quinidine, procainamide, amiodarone) and strong immunosuppressants.
Adverse Effects
Side effects of Etrasimod :
Common (≥5%): Headache, Elevated liver enzymes, Dizziness Other reported: Bradycardia, Hypertension, Nausea, Arthralgia, Urinary tract infection, Herpes viral infections, Hypercholesterolemia, Macular Edema, Cutaneous Malignancies, Posterior Reversible Encephalopathy Syndrome, Decreased lung function, Unintended Additive Immune System Effects
Mechanism of Action
Etrasimod is a next-generation, oral, selective sphingosine-1-phosphate (S1P) receptor modulator. It is primarily indicated for the treatment of moderately to severely active ulcerative colitis.
Unlike first-generation S1P modulators, etrasimod is designed to be highly selective for specific receptor subtypes, which helps optimize its therapeutic effect while minimizing certain side effects.
Note
Etragut 2 mg Tablet manufactured by Incepta Pharmaceuticals Ltd.. Its generic name is Etrasimod. Etragut is availble in Bangladesh.
DIMS information on Etragut Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.